Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, February 25, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Fri, February 22, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Adnan Butt Downgraded (BIIB) to Hold and Decreased Target to $325 on, Feb 22nd, 2019
Adnan Butt of Guggenheim, Downgraded "Biogen Inc." (BIIB) to Hold and Decreased Target from $410 to $325 on, Feb 22nd, 2019.
Adnan has made no other calls on BIIB in the last 4 months.
There are 3 other peers that have a rating on BIIB. Out of the 3 peers that are also analyzing BIIB, 1 agrees with Adnan's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Thomas Shrader of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $346 on, Thursday, February 21st, 2019
These are the ratings of the 2 analyists that currently disagree with Adnan
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $401 on, Wednesday, December 19th, 2018
- Cory Kasimov of "JP Morgan" Maintained at Buy with Decreased Target to $436 on, Wednesday, October 24th, 2018
